Head-to-head evidence
Elsulfavirine vs Ulonivirine
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
HIV
Shared mechanism: HIV reverse transcriptase · full HIV pipeline
Elsulfavirine · Elpida
Marketed by Viriom
NCT02489461 · Phase 2/3 · completed
The study randomized 150 participants and used double blinding with an active efavirenz comparator. Its primary endpoint was the proportion with HIV-1 RNA below 400 copies/mL at Week 12, but no results are posted, so the outcome comparison cannot be assessed.
Ulonivirine
Developed by Merck & Co.
NCT04564547 · Phase 2 · completed
Randomized, triple-masked phase 2b switch study of once-weekly islatravir plus ulonivirine in virologically suppressed HIV-1 infection (161 participants). All three primary endpoints are adverse-event rates reported descriptively; no efficacy comparison was posted as primary.
Next expected readout: August 2027 · NCT06891066 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Elsulfavirine's landscape · Ulonivirine's landscape